Publications by authors named "Jamie Garside"

Claim this Profile
A
A comparison by mismatch repair status of real-world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands.
Renee A Lunenberg, Ingrid A Franken, Frederieke H van der Baan, Femke P C Sijtsma, Geraldine R Vink, Jamie Garside

Int J Cancer· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Dana M Chase, Jørn Herrstedt, Eirwen M Miller, Lucy Gilbert, Oleksandr Zub, Jamie Garside

Int J Gynecol Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak, Jamie Garside

Int J Gynecol Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study.
Susana Banerjee, Alvaro Ingles Russo Garces, Jamie Garside, Tameera Rahman, Clare Pearson

BMJ Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Monica Kobayashi, Jamie Garside, Joehl Nguyen

J Health Econ Outcomes Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Jamie Garside, Qin Shen, Bernd Westermayer, Michiel van de Ven, Sonja Kroep

Clin Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Robert L Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi

J Health Econ Outcomes Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
Cara Mathews, Domenica Lorusso, Robert L Coleman, Susan Boklage, Jamie Garside

Oncologist· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
Zarmina S Khankhel, Sarah Goring, Sarah Bobiak, Francois-Xavier Lamy, Dweeti Nayak, Jamie Garside

Future Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma.
Neerav Monga, Jamie Garside, Matthew S Davids, Constantine Tam, Katherine Ward

Pharmacoecon Open· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
Neerav Monga, Constantine Tam, Jamie Garside, Matthew S Davids, Katherine Ward

Crit Rev Oncol Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews.
Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O'Donovan

Pharmacoecon Open· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review of the global burden of illness of mantle cell lymphoma.
Neerav Monga, Jamie Garside, Joan Quigley, Moira Hudson, Peter O'Donovan

Curr Med Res Opin· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Michael Herdman, Cicely Kerr, Marco Pavesi, Jamie Garside, Andrew Lloyd

J Patient Rep Outcomes· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Gilles Salles, Emmanuel Bachy, Lukas Smolej, Martin Simkovic, Lucile Baseggio, Jamie Garside

Ann Hematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A note on the relationship between age and health-related quality of life assessment.
Patricia Cubi-Molla, Koonal Shah, Jamie Garside, Mike Herdman, Nancy Devlin

Qual Life Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of illness of follicular lymphoma and marginal zone lymphoma.
Neerav Monga, Loretta Nastoupil, Jamie Garside, Joan Quigley, Moira Hudson

Ann Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
Jamie Garside, Nollaig Healy, Hervé Besson, Ruben Hermans, Finlay MacDougall

J Comp Eff Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis